Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Interim Management Statement

8 Jul 2009 16:43

RNS Number : 3640V
Aberdeen Income & Growth VCT PLC
08 July 2009
Β 

ο»Ώ

AberdeenΒ Income and GrowthΒ VCT PLCΒ (the Company)

Interim Management StatementΒ -Β Quarter ended 31 MayΒ 2009

ThisΒ Interim Management Statement,Β for theΒ quarterΒ endedΒ 31Β MayΒ 2009, is provided in accordance with Rule 4.3 of the Disclosure and TransparencyΒ Rules of the UK Listing AuthorityΒ andΒ also includes relevant informationΒ in respect of the period from 1Β JuneΒ 2009Β toΒ the date ofΒ issue.Β ThisΒ Statement has been prepared solely to provide additional informationΒ in orderΒ to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders,Β or any other party,Β for any other purpose.

1. FinancialΒ highlights

Β·; Net Asset Value* (NAV) of 64.1p per share at 31 May 2009 compared to 63.3p per share at 28 February 2009.
Β·; Final dividend of 2.0p per share to be paid on 24 July 2009, bringing total dividend payment for the year ended 28 February 2009 to 3.0p, equivalent to a yield of 5.0% from an equity investment to a higher-rate taxpayer on an effective initial investment of 80p per share when the initial tax relief of 20% is taken into account. On the current mid-market price of 37.5p, the equivalent yield from an equity investment to a higher-rate taxpayer would be 10.7%.

*The NAVΒ is unaudited andΒ reflects theΒ closingΒ bid priceΒ of quoted securitiesΒ atΒ 31Β MayΒ 2009. Unlisted companies areΒ normallyΒ valued on a six-monthly basis and the NAV incorporates the Directors'Β valuationΒ of unlistedΒ investmentsΒ asΒ atΒ 28Β February 2009, adjusted for subsequent events where appropriate.Β 

2. InvestmentsΒ and Disposals

During the quarter endedΒ 31Β MayΒ 2009,Β investmentsΒ totallingΒ Β£192,000 were madeΒ inΒ twoΒ unlisted companies.

There were no other material transactions during the period under review.Β 

3. RecentΒ developmentsΒ 

BetweenΒ 1Β JuneΒ 2009Β and the date of this statement,Β investments totallingΒ Β£1,124,000Β were madeΒ inΒ twoΒ unlistedΒ  companies

DuringΒ the same post quarter-end period, a combination of partial and complete disposals ofΒ twoΒ unlisted andΒ threeΒ AIM quoted investments generated aggregate proceeds of Β£1,242,000 against cost of Β£1,194,000.Β 

Other than described aboveΒ and changes inΒ theΒ value of investments quoted on regulated markets,Β theΒ Board is not aware of anyΒ material events during the period from 1Β MarchΒ toΒ 31Β MayΒ 2009,Β or in the periodΒ fromΒ 1Β JuneΒ 2009Β to the date of this announcement, which would haveΒ hadΒ a material impact on the financial position of the Company.

Issued on behalf of the Board

Maven Capital PartnersΒ UKΒ LLP, Secretary

8Β July 2009

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSUUUBWMUPBGAR
Date   Source Headline
26th Jun 20269:30 amRNSIssue of Equity
23rd Jun 20264:06 pmRNSAudited NAV - Dividend Investment Scheme
2nd Jun 20264:19 pmRNSAnnual Financial Report
1st May 20263:20 pmRNSTransaction in Own Shares
30th Apr 20265:09 pmRNSTransaction in Own Shares
30th Apr 202610:51 amRNSAdmission of Further Securities to Trading
29th Apr 202612:23 pmRNSIssue of Equity
27th Apr 20263:29 pmRNSUnaudited Net Asset Value and Dividend Declaration
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:17 amRNSAdmission of Further Securities to Trading
14th Apr 202611:06 amRNSIssue of Equity
8th Apr 20269:27 amRNSAdmission of Further Securities to Trading
25th Mar 202610:49 amRNSAdmission of Further Securities to Trading
24th Mar 202612:08 pmRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
29th Jan 20264:54 pmRNSTransaction in Own Shares
21st Jan 202611:01 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:39 amRNSIssue of Equity
15th Jan 202610:27 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 20269:50 amRNSIssue of Equity
14th Jan 20262:33 pmRNSUnaudited NAV - Dividend Investment Scheme
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:39 pmRNSResult of General Meeting
29th Oct 20257:00 amRNSHalf-year Report
16th Oct 20254:43 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:06 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:12 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:33 pmRNSTransaction in Own Shares
18th Jul 202510:08 amRNSIssue of Equity - Dividend Investment Scheme
16th Jul 20257:08 amRNSStatement re Offer for Subscription
11th Jul 20253:56 pmRNSStatement re Dividend Investment Scheme
11th Jul 20252:58 pmRNSStatement re Unaudited NAV and Interim Dividend
10th Jul 20252:32 pmRNSResult of AGM
28th May 20254:18 pmRNSAnnual Financial Report
7th May 20254:35 pmRNSTransaction in Own Shares
6th May 202511:51 amRNSIssue of Equity
25th Apr 20254:19 pmRNSUnaudited NAV and Proposed Final Dividend
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:15 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:02 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:23 pmRNSUnaudited Net Asset Value
29th Jan 20254:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.